ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2
Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2. The active...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; ger |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | ZINIC, MLADEN SUBOTIC, BORIS MIKLOSKA, ZORKA |
description | Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2. The active substance is represented by the synthetic zeolites in pure form, with defined crystal structures and chemical compositions. The active substance (zeolite) has a crystal size of 0.1-10 μm and specific surface of 400-1200 m2/g. The sodium ions can be partially or completely exchanged with other cations, e.g. K+, Ag+, NH4+, Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Fe2+ and Fe3+ in active substance of this antiviral compound. The carrier of active compound is the organic gel, water, oil, cream, liposome and liposome-based systems with regular and/or prolonged activity. The weight ratio between the active substance and the carrier is 5×10−9-10−3, i.e. 5 ng to 1 mg of active substance per one gram of the carrier. The additives used are vitamines: Vitamin C (0-20 wt. %), vitamin E (0-0.01 wt. %), vitamin A (0-1 wt. %) and vitamin D3 (0-1 wt. %). The efficacy of this preparation was demonstrated in in vitro experiments of the inhibition of HSV-1 and HSV-2 plaques formation in keratinocyte monolayers that were preincubated, coincubated or postincubated with the virus at the different time points (by up to 92%). |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP2296671A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP2296671A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP2296671A13</originalsourceid><addsrcrecordid>eNqNzEEKwjAUBNBuXIh6h7mAi1aouIztDw3UJCRptW5KkbgSLdR7eGUTFNeu_sC8-fPkdSZVC0fgyhyamjmhJJgs0ViCq8iQ4rGLGdpQS_JHYs10hyBKYYlZsihYGJbYdxCSUxGtxVG4CgHrAKw46JpOaIVpLFynCennW4zZMpldh9vkV9-7SMDJFdXaj4_eT-Nw8Xf_7Eln2S7PtylLN3-QN3-kP5s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2</title><source>esp@cenet</source><creator>ZINIC, MLADEN ; SUBOTIC, BORIS ; MIKLOSKA, ZORKA</creator><creatorcontrib>ZINIC, MLADEN ; SUBOTIC, BORIS ; MIKLOSKA, ZORKA</creatorcontrib><description>Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2. The active substance is represented by the synthetic zeolites in pure form, with defined crystal structures and chemical compositions. The active substance (zeolite) has a crystal size of 0.1-10 μm and specific surface of 400-1200 m2/g. The sodium ions can be partially or completely exchanged with other cations, e.g. K+, Ag+, NH4+, Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Fe2+ and Fe3+ in active substance of this antiviral compound. The carrier of active compound is the organic gel, water, oil, cream, liposome and liposome-based systems with regular and/or prolonged activity. The weight ratio between the active substance and the carrier is 5×10−9-10−3, i.e. 5 ng to 1 mg of active substance per one gram of the carrier. The additives used are vitamines: Vitamin C (0-20 wt. %), vitamin E (0-0.01 wt. %), vitamin A (0-1 wt. %) and vitamin D3 (0-1 wt. %). The efficacy of this preparation was demonstrated in in vitro experiments of the inhibition of HSV-1 and HSV-2 plaques formation in keratinocyte monolayers that were preincubated, coincubated or postincubated with the virus at the different time points (by up to 92%).</description><language>eng ; fre ; ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110323&DB=EPODOC&CC=EP&NR=2296671A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110323&DB=EPODOC&CC=EP&NR=2296671A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZINIC, MLADEN</creatorcontrib><creatorcontrib>SUBOTIC, BORIS</creatorcontrib><creatorcontrib>MIKLOSKA, ZORKA</creatorcontrib><title>ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2</title><description>Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2. The active substance is represented by the synthetic zeolites in pure form, with defined crystal structures and chemical compositions. The active substance (zeolite) has a crystal size of 0.1-10 μm and specific surface of 400-1200 m2/g. The sodium ions can be partially or completely exchanged with other cations, e.g. K+, Ag+, NH4+, Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Fe2+ and Fe3+ in active substance of this antiviral compound. The carrier of active compound is the organic gel, water, oil, cream, liposome and liposome-based systems with regular and/or prolonged activity. The weight ratio between the active substance and the carrier is 5×10−9-10−3, i.e. 5 ng to 1 mg of active substance per one gram of the carrier. The additives used are vitamines: Vitamin C (0-20 wt. %), vitamin E (0-0.01 wt. %), vitamin A (0-1 wt. %) and vitamin D3 (0-1 wt. %). The efficacy of this preparation was demonstrated in in vitro experiments of the inhibition of HSV-1 and HSV-2 plaques formation in keratinocyte monolayers that were preincubated, coincubated or postincubated with the virus at the different time points (by up to 92%).</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzEEKwjAUBNBuXIh6h7mAi1aouIztDw3UJCRptW5KkbgSLdR7eGUTFNeu_sC8-fPkdSZVC0fgyhyamjmhJJgs0ViCq8iQ4rGLGdpQS_JHYs10hyBKYYlZsihYGJbYdxCSUxGtxVG4CgHrAKw46JpOaIVpLFynCennW4zZMpldh9vkV9-7SMDJFdXaj4_eT-Nw8Xf_7Eln2S7PtylLN3-QN3-kP5s</recordid><startdate>20110323</startdate><enddate>20110323</enddate><creator>ZINIC, MLADEN</creator><creator>SUBOTIC, BORIS</creator><creator>MIKLOSKA, ZORKA</creator><scope>EVB</scope></search><sort><creationdate>20110323</creationdate><title>ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2</title><author>ZINIC, MLADEN ; SUBOTIC, BORIS ; MIKLOSKA, ZORKA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP2296671A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2011</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZINIC, MLADEN</creatorcontrib><creatorcontrib>SUBOTIC, BORIS</creatorcontrib><creatorcontrib>MIKLOSKA, ZORKA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZINIC, MLADEN</au><au>SUBOTIC, BORIS</au><au>MIKLOSKA, ZORKA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2</title><date>2011-03-23</date><risdate>2011</risdate><abstract>Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2. The active substance is represented by the synthetic zeolites in pure form, with defined crystal structures and chemical compositions. The active substance (zeolite) has a crystal size of 0.1-10 μm and specific surface of 400-1200 m2/g. The sodium ions can be partially or completely exchanged with other cations, e.g. K+, Ag+, NH4+, Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Fe2+ and Fe3+ in active substance of this antiviral compound. The carrier of active compound is the organic gel, water, oil, cream, liposome and liposome-based systems with regular and/or prolonged activity. The weight ratio between the active substance and the carrier is 5×10−9-10−3, i.e. 5 ng to 1 mg of active substance per one gram of the carrier. The additives used are vitamines: Vitamin C (0-20 wt. %), vitamin E (0-0.01 wt. %), vitamin A (0-1 wt. %) and vitamin D3 (0-1 wt. %). The efficacy of this preparation was demonstrated in in vitro experiments of the inhibition of HSV-1 and HSV-2 plaques formation in keratinocyte monolayers that were preincubated, coincubated or postincubated with the virus at the different time points (by up to 92%).</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; fre ; ger |
recordid | cdi_epo_espacenet_EP2296671A1 |
source | esp@cenet |
subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A18%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZINIC,%20MLADEN&rft.date=2011-03-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP2296671A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |